L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia
Sponsor: Emmaus Medical, Inc.
A PHASE2 clinical study on Sickle Cell Anemia and Thalassemia, this trial is completed. The trial is conducted by Emmaus Medical, Inc. and has accumulated 13 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Feb 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Apr 2017 — Aug 2017 [monthly]
Completed PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emmaus Medical, Inc.
- FDA Office of Orphan Products Development
For direct contact, visit the study record on ClinicalTrials.gov .